FDA advisers back vedolizumab approval to treat moderate to severe inflammatory bowel disease

SILVER SPRING, MD. – The benefits of vedolizumab, an integrin antagonist, outweigh the potential for progressive multifocal encephalopathy and other possible risks as a treatment for moderate to...